Physician profile
Robert D Hamilton
NPI 1154367837
$6,205.96
in general payments reported to CMS, 2019-2025
61 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,876 · 2020: $506 · 2021: $1,287 · 2022: $964 · 2023: $516 · 2024: $57.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $645.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $519.48 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Genentech USA, INC. | $426.04 | 2019-2022 | |
| Janssen Biotech, INC. | $413.27 | 2019-2023 | Tecvayli, Darzalex, Imbruvica |
| Pfizer INC. | $411.28 | 2019-2023 | |
| Amgen INC. | $397.43 | 2019-2022 | |
| Celgene Corporation | $391.79 | 2019-2023 | Reblozyl |
| Incyte Corporation | $301.34 | 2019-2023 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $293.62 | 2019-2022 | |
| Genzyme Corporation | $194.23 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.86 | 2019-2023 | Iclusig |
| Seagen INC. | $121.64 | 2020-2023 | Adcetris |
| Astellas Pharma US INC | $118.77 | 2019-2023 | Xospata |
| Ipsen Biopharmaceuticals, INC | $99.86 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $90.33 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.